{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:29Z","timestamp":1794587249077,"version":"4.9.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Drug-induced suicidality is a severe and frequently overlooked area within pharmacovigilance. While the traditional focus has centered on psychotropic medications, non-psychotropic drugs acting on histamine receptors may also induce depression and suicidality through central nervous system effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 33-year-old male presented with a chief complaint of \u201cdizziness for 1 week.\u201d His dizziness improved after taking a betahistine hydrochloride oral solution, but he subsequently developed symptoms including low mood, emotional detachment, and suicidal ideation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Given the close temporal relationship between drug intake and symptom onset, rapid improvement after withdrawal, and assessment by the Naranjo scale and World Health Organization\u2013Uppsala Monitoring Centre system, the depressive symptoms with suicidality were preliminarily judged to be \u201cprobable\u201d betahistine-associated adverse reactions (grade 1 [mild]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Betahistine was discontinued immediately and replaced with difenidol hydrochloride tablets to manage the dizziness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Suicidal ideation resolved completely within 2 days of betahistine discontinuation. No recurrence of psychiatric symptoms was reported during the 3-month follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case emphasizes the need for clinicians and pharmacists to move beyond the cognitive bias that only psychotropic drugs carry a significant suicide risk. Vigilance for potential neuropsychiatric adverse reactions, such as depression and suicidality, should be maintained for all drug classes, particularly for non-psychotropic agents acting on histamine receptors. Timely recognition and drug discontinuation are crucial to ensure patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049339","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:01:07Z","timestamp":1782108067000},"page":"e49339","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Suicidality associated with betahistine: A rare case report and systematic review of histaminergic drug-induced depression"],"prefix":"10.1097","volume":"105","author":[{"given":"Jiong","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chengdu Seventh People\u2019s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chengdu Seventh People\u2019s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3151-5659","authenticated-orcid":false,"given":"Xiaoli","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chengdu Seventh People\u2019s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","doi-asserted-by":"crossref","first-page":"e49755","DOI":"10.2196\/49755","article-title":"Assessing the labeling information on drugs associated with suicide risk: systematic review.","volume":"10","author":"Jeon","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"R2-20261113","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ijnp\/pyy048","article-title":"Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP multicenter drug safety surveillance project.","volume":"21","author":"St\u00fcbner","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"R3-20261113","doi-asserted-by":"crossref","first-page":"b2880","DOI":"10.1136\/bmj.b2880","article-title":"Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.","volume":"339","author":"Stone","year":"2009","journal-title":"BMJ"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/ph17121714","article-title":"Age-dependent analysis of suicidal ideation, suicide attempts, and suicides associated with SSRI and SNRI drugs based on pharmacovigilance data.","volume":"17","author":"Schetz","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20261113","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/00002018-200629110-00004","article-title":"Betahistine: a retrospective synopsis of safety data.","volume":"29","author":"Jeck-Thole","year":"2006","journal-title":"Drug Saf"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000515821","article-title":"Betahistine in m\u00e9ni\u00e8re\u2019s disease or syndrome: a systematic review.","volume":"27","author":"Van Esch","year":"2022","journal-title":"Audiol Neurootol"},{"key":"R8-20261113","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/wjo2.161","article-title":"Effectiveness of betahistine as an add-on therapy to epley maneuver for benign paroxysmal positional vertigo: a systematic review and meta-analysis.","volume":"11","author":"Alsolamy","year":"2025","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nrl.2015.01.003","article-title":"Behavioural and psychiatric symptoms in cognitive neurology.","volume":"32","author":"Robles Bay\u00f3n","year":"2017","journal-title":"Neurologia"},{"key":"R10-20261113","first-page":"5","article-title":"Study of the adverse reaction signals of betahistine based on FEARS database.","volume":"3","author":"Wang","year":"2022","journal-title":"Geriatr Res"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/15622975.2016.1224924","article-title":"Sleep disturbances and upregulation of brain arousal during daytime in depressed versus non-depressed elderly subjects.","volume":"18","author":"Ulke","year":"2017","journal-title":"World J Biol Psychiatry"},{"key":"R12-20261113","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/sleep\/31.6.777","article-title":"Neuroimaging insights into the pathophysiology of sleep disorders.","volume":"31","author":"Desseilles","year":"2008","journal-title":"Sleep"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/00016489709124020","article-title":"Physiopathology of H3-receptors and pharmacology of betahistine.","volume":"526","author":"Van Cauwenberge","year":"1997","journal-title":"Acta Otolaryngol Suppl"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00023210-200115110-00004","article-title":"Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.","volume":"15","author":"Lacour","year":"2001","journal-title":"CNS Drugs"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"111475","DOI":"10.1016\/j.pnpbp.2025.111475","article-title":"Advances in neurotransmitter-mediated prefrontal circuitry in depression.","volume":"141","author":"Li","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.npp.1300919","article-title":"Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients.","volume":"31","author":"Suzuki","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R17-20261113","doi-asserted-by":"crossref","first-page":"21295","DOI":"10.1038\/s41598-025-06403-0","article-title":"An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system.","volume":"15","author":"Tang","year":"2025","journal-title":"Sci Rep"},{"key":"R18-20261113","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/03009734.2018.1489918","article-title":"Desloratadine and depression, a drug safety signal based on worldwide spontaneous reporting of side effects.","volume":"123","author":"Boer","year":"2018","journal-title":"Ups J Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:01:41Z","timestamp":1794585701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":18,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049339","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2025-12-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}